India’s Tata Institute of Fundamental Research (TIFR) has announced the development of a new pro-oxidant tablet, combining resveratrol and copper (R+Cu), that has the potential to prevent the recurrence of cancer.

More than a decade of research at the Tata Memorial Centre has resulted in the creation of this tablet which will be priced at around Rs100 ($1.2), Indian media publication NDTV has reported.

The institute’s findings suggest that cancer cell remnants, known as cell-free chromatin particles (cfChPs), can induce cancer in healthy cells, leading to new tumour formation.

The R+Cu tablet, when ingested, produces oxygen radicals within the stomach.

These radicals are rapidly absorbed into the bloodstream, where they target and destroy cfChPs, hindering the process of metastasis—the spread of cancer cells to other body parts.

The tablet also reduces the toxicity associated with chemotherapy and diminishes the overall side effects of cancer treatment by around 50%.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It has shown 30% effectiveness in preventing cancer.

Its potential extends to the treatment of cancers including pancreatic, oral and lung.

Tata Memorial Hospital senior cancer surgeon Dr Rajendra Badve stated: “Tata doctors were working on this tablet for almost a decade.

“The tablet is awaiting approval from the Food Safety and Standards Authority of India (FSSAI). TIFR scientists have applied to FSSAI to approve this tablet.

“This tablet will be available everywhere for just Rs100.”

The institute plans to make the tablet available from June/July 2024 for cancer patients following approval from the Indian regulator.